Fifty1 AI Labs, a subsidiary of Fifty 1 Labs, Inc. (OTC: FITY), together with its commercial partner BioSpark AI Technologies Inc., is announcing a major milestone in its AI-driven drug repurposing ...

In a landmark move that signals a full alignment of interests, members of the BONK founding core group, including Mitchell Rudy (AKA Nom), will be appointed to the Safety Shot Board of Directors, ...

ALK (ALKB:DC / OMX: ALK B) today announced that the 2025 full-year financial outlook has been upgraded. Revenue is now expected to grow by 12-14% in local currencies (previously 9-13% growth).

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds. The RECELL System, excluding RECELL GO®, is ...

U.S. Food and Drug Administration (“FDA”) Breakthrough Device Designation (“BDD”) granted for atrioventricular interval modulation (“AVIM”) therapy in patients with uncontrolled hypertension and ...

NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (NASDAQ: TLRY and TSX: TLRY) is building on the ...

Phase 1b/2a immune thrombocytopenia (ITP) trial FPI achieved, enrollment ongoing. Climb Bio is enrolling an open-label, dose-escalation Phase 1b/2a clinical trial of budoprutug in patients with ITP to ...

BOSTON and LONDON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results and business highlights for ...

Revenues increased 46% year over year to $894 thousand in 2Q25 compared to $612 thousand in 2Q24. Operating expenses decreased 10% year over year in 2Q25 compared to 2Q24. Operating loss improved by ...

PHILADELPHIA, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, ...

Endure Biotherapeutics Receives SBIR Phase I Grant to Advance Engineered Native Bacteria Therapy for Familial A ...

Analysis of functional changes and biomarker activity at 90 days will be available during 4Q 2025 In July 2025 following the close of 2Q 2025, Gain completed an underwritten public offering that ...